KEYNOTE-555 Cohort B: Efficacy, safety, and PK of pembrolizumab (pembro) 400 mg every 6 weeks (Q6W) as 1L therapy for advanced melanoma Meeting Abstract
| Authors: | Jacobs, C. R.; Rapoport, B. L.; Chan, S. W.; Ruff, P.; Arance, A. M.; Mujika, K.; Anderson, J. R.; Lala, M.; Jain, L.; Akala, O. O.; Chartash, E.; Cohen, G. L. |
| Abstract Title: | KEYNOTE-555 Cohort B: Efficacy, safety, and PK of pembrolizumab (pembro) 400 mg every 6 weeks (Q6W) as 1L therapy for advanced melanoma |
| Meeting Title: | 2021 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 39 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2021 Jun 4-8 |
| Meeting Location: | Virtual |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2021-05-20 |
| Language: | English |
| ACCESSION: | WOS:000708120605143 |
| DOI: | 10.1200/JCO.2021.39.15_suppl.9541 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 9541 -- Source: Wos |
